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ABSTRACT 
Objective: The aim of the present study is to develop docetaxel-loaded nano liquid crystals (NLCs) to enhanced and effective delivery of the drug 
to the skin cancer.  
Methods: NLCs bearing docetaxel were prepared by an emulsification solvent diffusion method. The formulated NLCs were characterized for 
average particle size, polydispersity index (PDI) Zeta potential, entrapment efficiency and in vitro drug release study. The prepared formulations 
were studied for it's in vitro cell line and cell uptake study.  
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Results: It was revealed that the average size of NLCs was found 178.3±5.07, PDI was 0.189, percent entrapment efficiency was found 71.3±2.49 
and Zeta potential was found-17.3±2.4. In vitro release determined by Franz diffusion cell was found 61.6±3.2% after 72 hr. 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay shows that Docetaxel loaded NLCs were giving more cytotoxicity as compared to the plain drug. 
The cell uptake study was found enhanced uptake of fluorescein isothiocyanate (FITC) loaded NLCs in comparison to plain FITC. Docetaxel and 
docetaxel-loaded NLCs showed 28.3±0.3 and 39.3±1.3 growth inhibition respectively after 48h upon incubation at 0.5 µg/ml concentration 
(p<0.05).  
Conclusion: The result of the studies was concluded that NLCs can be used as impending drug delivery system which may enhance the drug uptake 
and maintain the drug level for longer period of time and it is potential carrier system which can be used for the treatment of skin diseases like 
cancer. 
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Melanoma, squamous cell carcinoma, and basal cell carcinoma are 
different types of skin cancer that are most commonly origin by 
extensive contact to sunlight and it is recognized by unwarranted 
propagation of these type of cells which generally results in damage 
of keratinocytes. Excessive UV exposure suppresses the expression 
of p53 suppressor gene, which plays a key role in the removal of 
sunburn cells and avoidance of basal cells transformation. Docetaxel 
used to treat a number of breast cancer, head and neck 
cancer, stomach cancer, prostate cancer, and non-small-cell lung 
cancer. It is the taxane family of medications. It works by disrupting 
the normal function of microtubules and thereby stopping cell 
division [1]. It may be used by itself or along with other 
chemotherapy medication. Common side effects include hair 
loss, low blood cell counts, numbness, and irregular breathing and 
muscle pains. Unwanted drug distributions or chemotherapeutic 
failure is the major reason behind these side effects and it is 
necessary to design a suitable drug delivery system and select a 
route of administration which overcomes above side effect by 
preventing the unwanted distribution of drug [2, 3]. A need for the 
simple, safe and stable formulation is necessary. Nano Liquid 
Crystals (NLCs) are a novel drug delivery systems have properties 
and advantages like NLCs and lipid NLCs [5]. NLCs are non-toxic and 
can be prepared without the use of toxic materials [6]. They are 
capable to protect the drug molecules against degradation and 
provide sustained release pattern [7, 8]. The topical administration 
of Docetaxel-loaded NLCs for skin cancer can be minimizing the side 
effects of Docetaxel and increase therapeutic effectiveness [3]. The 
nanosize of NLCs promotes drug absorption through the stratum 
corneum, it is the outermost barrier of epidermis that able to retard 
the drug penetration into the skin [9]. Aim of this study was to 
investigate and assess the potential of Docetaxel-loaded NLCs for the 
treatment of skin cancer using skin cancer cell line [2, 10, 11]. 
MATERIALS AND METHODS 
Materials 
Docetaxel was obtained as a gift sample from Sun Pharma Pvt Ltd. 
Ahmadabad, India. Stearic acid was purchased from Himedia, 
Mumbai, India. Oleic acid was purchased from Loba Chemical, 
Mumbai, India. Tristearin, cholesterol, and soya PC were purchased 
from Sigma Aldrich, USA. Other chemicals and solvents were used of 
analytical reagent grade.  
Preparation of docetaxel loaded NLCS 
The docetaxel-loaded NLCs were prepared solvent diffusion melt 
dispersion techniques according to Selvamuthukumar et al., 2012 
[12]. The lipid, stearic acid (3.0%w/v), oleic acid (0.5% w/v), 
tristearin (1.0%w/v), cholesterol (0.75%) and soya 
phosphatidylcholine (1.5%w/v) were dissolved in 10 ml of ethanol: 
acetone solvent system in a 250 ml of beaker. Drug (docetaxel 
20%w/w of lipid) was added to above mixture. The mixture was 
melted 70 °C to get a clear lipid phase. In a separate beaker, 60 ml of 
double-distilled water containing tween 80 was stirred under 
magnetic stirrer and then heated at 70 °C with heating mental. The 
aqueous phase was maintained at 70ᵒC and kept under the high-
speed homogenizer (IKA T 25 digital ULTRA-TURRAX®, Germany) 
at 10000 rpm to make microemulsion. The oil phase containing drug 
was added dropwise to the aqueous phase using preheated (at 70 
°C) hypodermic syringe. After 30 min of stirring, heating was 
stopped. Then 20 ml of cold water was added dropwise to reduce 
the temperature of the dispersion. The dispersion was continuously 
stirred for 2 hr to the removal of ethanol and acetone from the NLCs. 
After stirring the prepared formulation was lyophilized using 
Labconco freeze dryer (Labconco, Cascade Freezone Plus 4.5 L 
Benchtop Freeze dryer, USA) and stored at 2-8 °C until further used 
for characterization. 
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Preparation of gel base 
Carbopol 934 (1-3%w/v) was accurately weighed and dispersed 
into double distilled water (80 ml) in a beaker. This solution was 
stirred continuously at 800 rpm for 1 hour and then 10 ml of 
propylene glycol was added to this solution. The obtained slightly 
acidic solution was neutralized by dropwise addition of 0.05 N 
sodium hydroxide solutions, and again mixing was continued until 
gel becomes transparent. The volume of the gel was adjusted to 100 
ml and then sonicated for 10 min on bath sonicator to remove air 
bubbles. Final pH of the gel base was adjusted to 6.5 [13]. The gel 
was also prepared with the plain drug by adding 10 mg of drug and 
dispersed properly by following the same procedure given above. 
The same procedure was used to formulate nanocarriers containing 
gel in which previously prepared NLCs were added in place of plain 
drug. The NLCs preparation corresponding to 6.0 % w/w (6.0 mg of 
drug in 100 mg of gel) of the drug was incorporated into the gel base 
to get the desired concentration of drug in a gel base. 
Characterizations of docetaxel-loaded NLCS 
Determination of particle size, PDI and surface charge 
Mean particle size distribution of Docetaxel-NLCs formulations and 
polydispersity index (PDI) of the NLCs were determined by photon 
correlation spectroscopy using a Zetasizer DTS, version 4.10 
(Malvern Instrument, UK). Before analysis, the formulations were 
diluted with 1:9 v/v with deionized water. The particles size and PDI 
were represented by the average diameter of the Gaussian 
distribution function in the logarithmic axis mode. Surface charge 
measurement of the NLCs was based on the zeta potential (ε) that 
was calculated according to Helmholtz–Smoluchowsky from their 
electrophoretic mobility. Zeta potential was determined by a 
Zetasizer (Zetasizer Nano ZS, Malvern Instruments, UK) with a field 
strength of 20 V/cm on a large bore measures cell. Before analysis, 
samples were diluted with 0.9 % NaCl to adjust the conductivity of 
50 μS/cm [14]. Particle size, size distribution, and zeta potential the 
prepared formulation was performed at the SAIL, School of 
Pharmaceutical Sciences, Rajiv Gandhi Proudyogiki Viswavidyalaya, 
Bhopal (MP), India. 
Shape and surface morphology 
The shape and surface morphology were examined by Transmission 
electron microscopy and scanning electron microscopy (SEM). For 
the SEM analysis, the prepared NLCs were sprinkling on a double 
adhesive tape which was stuck on an aluminum stub. The stubs were 
then coated with a gold layer about 300 Å of thickness using a 
sputter coater. The photomicrographs of prepared NLCs were taken 
with SEM (FESEM, GeminiO, Giess, Netherlands).  
The shape of the NLCs was determined by Transmission Electron 
Microscopy (TEM; Philips CM12 Electron Microscope, Eindhoven, 
Netherlands). For the TEM, the samples were prepared by taking 
one drop NLCs dispersion and a copper grid was placed on it. After 
60 seconds the grid was removed and excess of liquid was soaked 
with filter paper. Then the grid was negatively stained with 2.0 % 
phosphotungstic acid solution at a 20 kV acceleration voltage. The 
TEM images of prepared NLCs were taken which was shown in fig. 
2(a) and 2(b). Analysis of sample on SEM and TEM was carried out 
at IISER, Bhopal, India [14-16].  
Determination of entrapment efficiency (EE) 
The entrapment efficiency of prepared NLCs was determined 
according to Gupta et al., (2007) [14]. The lyophilized formulation 
equivalent to 10 mg of drug was taken and dissolved in 50 ml of a 
beaker containing 10 ml of ethanol. The solution was then 
centrifuged at 10000 rpm for 10 min. The 1.0 ml of the supernatant 
solution was withdrawal with the help of micropipette and transfer 
into a 10 ml of volumetric flask. The volume was made upto 10 ml 
with ethanol and analyze spectroscopically for drug content using 
Simadzu 1700 UV-spectrophotometer and it was calculated 
according to the formula given below. 
 
Characterization of NLCS containing gel 
Measurement of viscosity 
Viscosity measurements of prepared topical NLCs based gel were 
measured by Brookfield viscometer using spindle no. 63 with the 
optimum speed of 10rpm; viscosity was found to be 3776cps. 
Drug content 
Accurately weighed equivalent to 100 mg of topical NLCs gel was 
taken in a beaker and added 20 ml of 0.01N HCl. This solution was 
mixed thoroughly and filtered using Whatman filter paper no.1. 
Then 1.0 ml of filtered solution was taken in 10 ml capacity of 
volumetric flask and volume was made up to 10 ml with 0.01 N HCL 







nm. Drug content of NLCs based gel is shown in table 1. 
Extrudability study 
Extrudability was based upon the quantity of the gel extruded from 
the collapsible tube on the application of a certain load. More the 
quantity of gel extruded shows better extrudability. It was 
determined by applying the weight on the gel-filled collapsible tube 
and recorded the weight on which gel was extruded from the tube. 
Extrudability of gel required 170 grams of weight to extrude a 0.6 
cm ribbon of gel in 6 seconds [13]. 
Spreadability
 
Spreadability of the formulation is necessary to provide sufficient 
dose available to absorb from the skin to get a good therapeutic 
response. It was determined by the method reported by Khan et al., 
(2013) [15]. An apparatus in which a slide fixed on a wooden block 
and the upper slide has movable and one end of movable slide tied 
with weight pan. To determine spreadability, placing 2-5 g of gel 
between two slides and gradually weight was increased by adding it 
on the weight pan and time required by the top plate to cover a 
distance of 10 cm upon adding 80g of weight was noted. Good 
spreadability show lesser time to spread [13, 15]  
 
In vitro drug diffusion study 
The in vitro diffusion study is carried by using Franz Diffusion Cell. 
Egg membrane is taken as a semi-permeable membrane for 
diffusion. The Franz diffusion cell has a receptor compartment with 
an effective volume of approximately 60 ml and an effective surface 
area of permeation 3.14sq. cms. The egg membrane is mounted 
between the donor and the receptor compartment. A two cm2
Cell cytotoxicity assay (MTT assay) for the optimized formulation 
was performed using B16F10 skin cancer (melanoma) cells lines 
from Advanced Centre for Treatment, Research and Education in 
Cancer (ACTREC), Tata Memorial Hospital (TMH), Mumbai, Cancer 
size 
patch taken and weighed then placed on one side of the membrane 
facing the donor compartment. The receptor medium is phosphate 
buffer pH 7.4. The receptor compartment is surrounded by a water 
jacket so as to maintain the temperature at 32±0.5 °C. Heat is 
provided using a thermostatic hot plate with a magnetic stirrer. The 
receptor fluid is stirred by Teflon coated magnetic bead which is 
placed in the diffusion cell [5]. During each sampling interval, 
samples are withdrawn and replaced by equal volumes of fresh 
receptor fluid on each sampling. The samples withdrawn are 
analyzed spectrophotometrically at a wavelength of the drug (fig. 2) 
Stability studies 
Stability study was carried out for drug-loaded NLCs at two different 
temperatures i.e. refrigeration temperature (4.0±0. 2 °C) and at 
room temperature (25-28±2 °C) for 3 w. The formulation subjected 
to stability study was stored in borosilicate container to avoid any 
interaction between the formulation and glass of container. The 
formulations were analyzed for any physical changes and drug 
content (table 2) [16]. 
Cell culture and mtt assay 
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cells were cultured in RPMI 1640 medium and added 10% of FBS, 
and 100 g/ml of streptomycin at 37 °C into CO2 incubator. After 
reaching 70% convergence cells were seeded in a 96 well microplate 
with 1000 µl of growth medium. The prepared samples of the plain 
drug and optimized formulation of NLCs were added in the 96 well 
plates in order to increase the concentration of Docetaxel then cells 
were incubating for 24 hr. After incubation, 200 µl of fresh media 
containing 20 µl of MTT solution was added and then incubated it 
for 4 hr at 37 °C. After incubation, media was replaced with 200 µl of 
DMSO to dissolve Formazan crystals. The 96 well plate was analyze 
using microplate reader by taking absorbance at 570 nm [5]. 
Cell uptake assay 
Preparation of fluorescein isothiocyanate loaded NLCs 
NLCs formulation containing fluorescent label (with fluorescein 
isothiocyanate (FITC)) were prepared to add 0.04 % of FITC in place 
of the drug to the lipid. The fluorescent NLCs were prepared 
according to the method used for the preparation of docetaxel-
loaded NLCs [6, 7]. 
Fluorescence microscopy 
Qualitative Cellular uptake of conjugates was determined with the 
following procedure. Briefly, the optimized formulation was 
previously labeled with fluorescein isothiocyanate (FITC) solution. 
2.5 x 105 cells/well were seeded in a six-well plate and incubated for 
24 h at 37 °C with 5% CO2
RESULTS AND DISCUSSION 
, and then the medium in each well was 
replaced with 2 ml of medium containing labeled formulation and 
plain FITC. The fluorescence due to the uptake of the fluorescent-
labeled formulation was analyzed under an inverted fluorescent 
microscope (Labomed, Germany) after 4, 12, 24, and 48 h [5]. 
Prepared formulations of NLCs were optimized on the basis of particle 
size, shape, surface charge, and entrapment efficiency. The particle 
size of NLCs determined by the light scattering method (Malvern 
Zetasizer, ZEM 5002, and UK) and found that the average particle size 
of optimized formulation was 178.37±5.07 nm. The PDI was found 
0.189 and Zeta potential was-17.3±2.4 (table 1) [14, 16, 17]. It was 
observed that the particles size of NLCs was increase with increasing 
the concentration of stearic acid and similarly particle size was 
decease with increasing the concentration of tween 80, stirring 
speed and increasing the sonication time. The size reduction may be 
due to surfactant action of surfactant, mechanical force and 
sonication wave force was responsible respectively for reducing the 
size of particles [18]. There was no significant difference in average 
particle size was observed with increasing the drug concentration. 
But in increasing the sonication time the size particle was 
decreasing from 218.42±6.09 to 145.29±7.80 after 90 sec of 
sonication. The low PDI value represents the uniformity of 
formulation in which there is no major difference in the size of 
particles. The PDI of optimized formulation was found at 0.189. PDI 
of the formulation was varied with increasing or decreasing the 
concentration ratio of lipid and surfactant and sonication time [16]. 
It was observed that when the lipid ratio in formulations was 
decreased and surfactant concentration was increased then the PDI 
was found decrease. When, sonication time increase from 30 to 90 
second, then PDI was 0.309, 0.189 and 0.487, respectively for 
different NLCs formulations. It was observed that on 90 second of 
sonication time the PDI was increased and it was due to the high 
mechanical forced of sonication waves which were resultant in heat 
generation which leads to agglomerates or denaturing the lipid 
molecules after breaking the particles [19-22]. 
 
Table 1: Characterization of optimized formulation of NLCs 
Characterization Average vesicle size (nm) % Entrapment efficiency PDI Zeta potential (mV) 
Doce-NLCs 178.3±5.07 71.3±2.49 0.189 -17.3±2.4 
Value represent as mean±SD (n=6) 
 
The shape and surface morphology of prepared NLCs was 
determined by using TEM and SEM. The photomicrograph was 
taken which shown in fig. 1 and was found that they were 
spherical in shape with smooth in the surface. The % 




Fig. 1: SEM (a) and TEM (b) photomicrograph of optimized NLCs formulation at 1000KX 
 
It was observed that the percent drug entrapment was decreasing 
with increasing the concentration of surfactant and on increasing the 
time of sonication. It is due to the extract out the drug from particles 
on increasing the mechanical force by sonication and size reduction of 
size NLCs on increasing the concentration of surfactant due to their 
surfactant action [16, 23-26]. Stability study data was revealed that the 
optimized formulation stable after 3 mo of storage at 4ᵒC while at 25-
28±2 °C, the formulation was found unstable. Stability of formulation 
was observed on the basis of % drug remain, average particles size 
and physical appearance. The average particle size of NLCs was found 
178.37±5.07, 179.32±2.49 and 186.84±5.84 nm after 1, 2 and 3 mo of 
storage at 4.0±0.2 °C while at 25-28±2 °C the average particle size was 
found 192.56±3.43, 238.54±4.87 and 583.54±6.99 nm after 1, 2 and 3 
mo of storage. Drug remaining in NLCs formulation was 48.62±1.39, 
35.29±1.08 and 23.83±2.11 % after 1, 2 and 3 mo of storage at 25-
28±2 °C while there were no significant changes in % drug remains 
and physical appearance in NLCs formulation was observed after 3 mo 
of storage at 4ᵒC. (table 2). 
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Table 2: Stability study of optimized formulation of NLCs 
Characteristic Time (mo) 
1 mo 2 mo 3 mo 
Temperature 4.0±0. 2 °C 25-28±2 °C 4.0±0. 2 °C 25-28±2 °C 4.0±0. 2 °C 25-28±2 °C 
Average particle size (nm) 178.3±5.07 192.5±3.43 179.32±2.49 238.5±4.87 186.8±5.84 583.5±6.99 
% EE 67.3±2.52 48.6±1.39 62.3±2.52 35.2±1.08 52.3±2.52 23.8±2.11 
Physical Appearance Normal High turbid Normal High turbid and 
agglomeration 
Normal High turbid and 
agglomeration 
Value represents as mean±SD (n=6) 
 
Prepared gel was evaluated for viscosity, % entrapment, 
extrudability, spreadability, and drug release study. It was found 
that viscosity of prepared gel was 178.37±5.07 cps, % Entrapment 
efficiency was 71.03±2.49%, Extrudability was 170 g and 
Spreadability (g. cm/sec) was found that 5.16 (g. cm/sec) 
respectively (table 2). 
  












3776 71.03±2.49 61.6±3.2 170 5.16 
Value represents as mean±SD (n=6)
 
 
In vitro drug release from NLCs was carried out using Frenze 
diffusion cell method and found 61.6±3.2% in 72 hr. In the first 30 
min, it was 12.45±0.9% drug release which slightly high. It was due 
to the release of free drug present in the bag after leaching from 
NLCs [27-29]. Drug release from NLCs formulation was found in a 
very sustained and controlled manner and follow Higuchi and 
Korsmeyer Peppas release kinetic. Drug release in 24 hr was 
41.36±1.8 and 52.06±2.6 in 48 hr (fig. 2).  
In vitro cell line study data shown that Docetaxel loaded NLCs was 
entered by the cancer cells and retard the growth by killing them in 
very low concentrations [6]. In vitro cytotoxicity using B16F10 was 
evaluated for plain docetaxel and docetaxel-loaded NLCs 
formulations in the concentration range of 0.05-0.5 µM of docetaxel. 
However, docetaxel and docetaxel-loaded NLCs showed 28.3±0.3 
and 39.3±1.3 growth inhibition respectively after 48h upon 
incubation at 0.5 µg/ml concentration (fig. 7.2). This was due to the 
high penetration of docetaxel-loaded NLCs into cancer cells. The 
value of IC50 for docetaxel and docetaxel-loaded NLCs was found to 
be 0.2 µg/ml and 0.1µg/ml following 24 hr and 48 hr incubation, 
respectively which was more than 5-fold lower as compared to free 
docetaxel (fig. 3). 
 
 
Fig. 2: In vitro drug release of gel-based NLCs, the value represents as mean±SD (n=6) 
 
Qualitative (Fluorescence) uptake study of FITC and FITC loaded 
NLCs was performed to assess the capability of NLCs to penetrate 
skin cancer cell lines. Similar to the results of the percent cell growth 
inhibition assay, uptake studies also displayed higher uptake of 
NLCs in comparison to plain FITC (fig. 4). Uptake of FITC loaded 
NLCs by cancer cells showed an enhanced uptake of the fluorescent 
marker after 4 hr of incubation. A slight uptake was observed with 
the cell treated with free FITC [6-8]. 
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Fig. 3: In vitro cytotoxicity of DOCE and DOCE-NLCs formulations (Percent Cell Growth Inhibition Assay) on skin cancer cell line, the value 
represents as mean±SD (n=6) 
 
 




Data are expressed as the mean±SD and statistical analysis was 
carried out using one-way ANOVA test using the Graph Pad PRISM 
software. A value of P
CONCLUSION 
<0.005 was measured, which was statistically 
significant [16, 29]. 
We have demonstrated that NLCs are promising colloidal 
Nanosystems for dermal delivery of Docetaxel through the in vitro 
and in vivo studies. NLCs suspension enhances Docetaxel 
permeability and picks it up to cancer cells and decreases cell 
viability at different concentration. According to cell uptake study, a 
substantial improvement in the restriction of cancer cell was found. 
Further studies are necessary for the determination of long-term 
Docetaxel-NLCs stability and the lack of cytotoxicity on the various 
untargeted organs to exploit this carrier can be used for the 
treatment of skin cancer. 
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